πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Arcellx, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

BioAtla, Inc.

BioAtla, Inc. logo
Market Cap: Low
Employees: Low

BA3011

Bio Atla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Their lead product candidate is BA3011, targeting various cancers.

Tags: antibody-based therapeutics, biopharmaceutical, cancer, clinical stage, solid tumor

Symbol: BCAB

Recent Price: $0.59

Industry: Biotechnology

CEO: Dr. Jay M. Short Ph.D.

Sector: Healthcare

Employees: 65

Address: 11085 Torreyana Road, San Diego, CA 92121

Phone: 858 558 0708

Last updated: 2024-12-31

Arcellx, Inc.

Arcellx, Inc. logo
Market Cap: High
Employees: Low

CART-dd BCMA

Arcellx, Inc. is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer and other incurable diseases, with a focus on its lead product candidate, CART-dd BCMA, for treating relapsed or refractory multiple myeloma.

Tags: acute myeloid leukemia, biotechnology, cancer treatment, clinical-stage, immunotherapy, multiple myeloma, myelodysplastic syndrome

Symbol: ACLX

Recent Price: $78.35

Industry: Biotechnology

CEO: Mr. Rami Elghandour

Sector: Healthcare

Employees: 130

Address: 25 West Watkins Mill Road, Gaithersburg, MD 20878

Phone: 240 327 0603

Last updated: 2024-12-31

Agenus Inc.

Agenus Inc. logo
Market Cap: Low
Employees: Medium

Retrocyte Display

Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products, offering antibody expression platforms, vaccine programs, and various monoclonal antibodies for cancer treatment.

Tags: antibody expression, cancer treatment, clinical trials, immuno-oncology, vaccine development

Symbol: AGEN

Recent Price: $2.69

Industry: Biotechnology

CEO: Dr. Garo H. Armen Ph.D.

Sector: Healthcare

Employees: 389

Address: 3 Forbes Road, Lexington, MA 02421-7305

Phone: 781 674 4400

Last updated: 2024-12-31

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

UCART19

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.

Tags: CAR T cell, allogeneic T cell therapies, cancer treatment, clinical trials, immuno-oncology

Symbol: ALLO

Recent Price: $2.10

Industry: Biotechnology

CEO: Dr. David D. Chang M.D., Ph.D.

Sector: Healthcare

Employees: 232

Address: 210 East Grand Avenue, South San Francisco, CA 94080

Phone: 650 457 2700

Last updated: 2024-12-31

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

T-cell immunotherapy treatments

Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.

Tags: Autoimmune Diseases, Biotherapeutics, Cancer Treatment, Immunotherapy, T-Cell Therapy, Viral Diseases

Symbol: ATRA

Recent Price: $13.28

Industry: Biotechnology

CEO: Dr. Anhco Nguyen Ph.D.

Sector: Healthcare

Employees: 165

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 650 278 8930

Last updated: 2024-12-31

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

IGALMI

Bio Xcel Therapeutics, Inc. is a biopharmaceutical company leveraging artificial intelligence for developing transformative medicines in neuroscience and immuno-oncology. It focuses on re-innovating existing drugs with machine learning to identify new therapeutic uses.

Tags: agitation treatment, artificial intelligence, biopharmaceutical, clinical trials, immuno-oncology, neuroscience

Symbol: BTAI

Recent Price: $0.37

Industry: Biotechnology

CEO: Dr. Vimal D. Mehta Ph.D.

Sector: Healthcare

Employees: 74

Address: 555 Long Wharf Drive, New Haven, CT 06511

Phone: 475 238 6837

Last updated: 2024-12-31

Cabaletta Bio, Inc.

Cabaletta Bio, Inc. logo
Market Cap: Low
Employees: Low

DSG3-CAART

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its leading product, DSG3-CAART, is in Phase I trials for treating mucosal pemphigus vulgaris.

Tags: CAAR T cells, T cell therapies, autoimmune diseases, biotechnology, clinical trials

Symbol: CABA

Recent Price: $2.24

Industry: Biotechnology

CEO: Dr. Steven A. Nichtberger M.D.

Sector: Healthcare

Employees: 136

Address: 2929 Arch Street, Philadelphia, PA 19104

Phone: 267 759 3100

Leadership

  • Steven Nichtberger, M.D., President, Chief Executive Officer, and Co-Founder
  • Samik Basu, M.D., Chief Scientific Officer
  • Gwendolyn Binder, Ph.D., President, Science & Technology
  • David J. Chang, M.D., M.P.H, FACR, Chief Medical Officer
  • Arun Das, M.D., Chief Business Officer
  • Michael Gerard, General Counsel
  • Heather Harte-Hall, Chief Compliance Officer
  • Anup Marda, Chief Financial Officer
  • Martha O’Connor, Chief Human Resources Officer
  • Sarah Yuan, Ph.D., Chief Technology Officer
  • Catherine Bollard, M.D., Independent Director, George Washington University
  • Scott Brun, M.D., Independent Director, formerly at AbbVie
  • Richard Henriques, M.B.A., Independent Director, former CFO of Gates Foundation, former Controller at Merck
  • Mark Simon, M.B.A., Independent Director, Torreya Partners
  • Shawn Tomasello, M.B.A., Independent Director, former CCO of Kite Pharma, Inc.

Last updated: 2024-12-31

Celularity Inc.

Celularity Inc. logo
Market Cap: Lowest
Employees: Low

CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.

Tags: biotechnology, cancer, cell therapies, immune diseases, infectious diseases, placental-derived

Symbol: CELU

Recent Price: $2.05

Industry: Biotechnology

CEO: Dr. Robert Joseph Hariri M.D., Ph.D.

Sector: Healthcare

Employees: 120

Address: 170 Park Avenue, Florham Park, NJ 07932

Phone: 908 768 2170

Leadership

  • Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
  • David Beers, CFA, Chief Financial Officer
  • Stephen Brigido, DPM, President, Degenerative Diseases
  • John Haines, Global Manager and Chief Administrative Officer
  • K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
  • John Colerangle, DVM, Ph.D., Regulatory Affairs
  • Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
  • Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
  • Carmine Palummo, Corporate Operations
  • Tim Wilk, Technical Operations
  • Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
  • Peter Diamandis, M.D., Director
  • Dean Kehler, Director
  • Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
  • Diane Parks, Director

Last updated: 2024-12-31

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. logo
Market Cap: High
Employees: Low

therapeutic monoclonal and bispecific antibodies

Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies for treating inflammatory diseases and cancers.

Tags: biopharmaceutical, bispecific antibodies, cancer treatment, inflammatory diseases, monoclonal antibodies

Symbol: CLDX

Recent Price: $25.12

Industry: Biotechnology

CEO: Mr. Anthony S. Marucci M.B.A.

Sector: Healthcare

Employees: 160

Address: Perryville III Building, Hampton, NJ 08827

Phone: 908 200 7500

Leadership

  • Anthony S. Marucci, Founder, President, Chief Executive Officer and Director
  • Tibor Keler, Ph.D., Founder, Executive Vice President and Chief Scientific Officer
  • Diane C. Young, M.D., Senior Vice President and Chief Medical Officer
  • Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
  • Sam Martin, Senior Vice President and Chief Financial Officer
  • Ronald A. Pepin, Ph.D., Senior Vice President and Chief Business Officer
  • Richard Wright, Ph.D., Senior Vice President and Chief Commercial Officer
  • Sarah Cavanaugh, Senior Vice President, Corporate Affairs and Administration
  • Margo Heath-Chiozzi, M.D., Senior Vice President, Regulatory Affairs
  • Freddy A. Jimenez, Esq., Senior Vice President and General Counsel
  • Karen L. Shoos, J.D., Former Chair, Director of Operations, Maryland Tech Council Venture Mentoring Services Program
  • Keith L. Brownlie, Former Partner, Ernst & Young LLP
  • Herbert J. Conrad, Former President, Roche Pharmaceuticals US
  • James J. Marino, J.D., Former Partner, Dechert LLP
  • Harry H. Penner, Jr., J.D., L.L.M., Former Chairman and CEO, Nascent Bioscience
  • Cheryl L. Cohen, President, CLC Consulting; Former Chief Commercial Officer of Medivation, Inc.
  • Dr. Garry Neil, Chief Executive Officer; Chair of the Board, Avalo Therapeutics
  • Rita Jain, M.D., Former Executive Vice President, Chief Medical Officer of ChemoCentryx, Inc.
  • Carl June, M.D.,
  • Michel Nussenzweig, M.D., Ph.D.,
  • Marc E. Rothenberg M.D., Ph.D.,
  • Joseph Schlessinger, Ph.D.,
  • Louis Weiner, M.D.,

Last updated: 2024-12-31

Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. logo
Market Cap: Low
Employees: Lowest

CLR 131

Cellectar Biosciences, Inc. is a clinical biopharmaceutical company concentrating on the development and commercialization of drugs for cancer treatment.

Tags: biopharmaceutical, cancer treatment, drug development, phospholipid drug conjugate

Symbol: CLRB

Recent Price: $0.29

Industry: Biotechnology

CEO: Mr. James V. Caruso

Sector: Healthcare

Employees: 20

Address: 100 Campus Drive, Florham Park, NJ 07932

Phone: 608 441 8120

Leadership

  • James Caruso, President, CEO and Director
  • Chad Kolean, Chief Financial Officer
  • Shane Lea, Chief Commercial Officer
  • Jarrod Longcor, Chief Operating Officer
  • Andrei Shustov, Senior Vice President, Medical
  • Douglas J. Swirsky, Chairman of the Board
  • Asher Alban Chanan-Khan, MD., Director
  • Frederick W. Driscoll, Director
  • Stefan D. Loren, Ph.D., Director
  • John Neis, Director
  • Cellectar Biosciences, Inc., Company Information

Last updated: 2024-12-31

Caribou Biosciences, Inc.

Caribou Biosciences, Inc. logo
Market Cap: Low
Employees: Low

CB-010, CB-011, CB-012, CB-020

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors, with several product candidates in clinical trials.

Tags: CAR-NK, CAR-T, biopharmaceutical, cell therapies, clinical-stage, genome-edited therapies, hematologic malignancies, solid tumors

Symbol: CRBU

Recent Price: $1.61

Industry: Biotechnology

CEO: Dr. Rachel E. Haurwitz Ph.D.

Sector: Healthcare

Employees: 158

Address: 2929 7th Street, Berkeley, CA 94710

Phone: 510 982 6030

Last updated: 2024-12-31

Precision BioSciences, Inc.

Precision BioSciences, Inc. logo
Market Cap: Lowest
Employees: Low

ARCUS

Precision Bio Sciences, Inc. is a clinical stage gene editing company specializing in in vivo gene editing and ex vivo allogeneic CAR T therapies, including the ARCUS genome editing platform and various investigational CAR T immunotherapies.

Tags: CAR T therapies, allogeneic CAR T, clinical stage, gene editing, genetic disorders, immunotherapy

Symbol: DTIL

Recent Price: $4.26

Industry: Biotechnology

CEO: Mr. Michael Amoroso

Sector: Healthcare

Employees: 109

Address: 302 East Pettigrew Street, Durham, NC 27701

Phone: 919 314 5512

Last updated: 2024-12-31

Legend Biotech Corporation

Legend Biotech Corporation logo
Market Cap: Highest
Employees: High

LCAR-B38M

Legend Biotech Corporation is a clinical-stage biopharmaceutical company focusing on the discovery and development of novel cell therapies for oncology and other indications globally.

Tags: CAR-T, biopharmaceutical, cell therapy, clinical trials, lymphoma, multiple myeloma, oncology

Symbol: LEGN

Recent Price: $32.77

Industry: Biotechnology

CEO: Dr. Ying Huang Ph.D.

Sector: Healthcare

Employees: 2200

Address: 2101 Cottontail Lane, Somerset, NJ 08873

Phone: 732 317 5050

Leadership

  • Ying Huang, Ph.D., CHIEF EXECUTIVE OFFICER
  • Guowei Fang, Ph.D., CHIEF SCIENTIFIC OFFICER AND HEAD OF BUSINESS DEVELOPMENT
  • Lori Macomber, CHIEF FINANCIAL OFFICER
  • Mythili Koneru, M.D., Ph.D., CHIEF MEDICAL OFFICER
  • Jim Pepin, GENERAL COUNSEL
  • Steve Gavel, SENIOR VICE PRESIDENT, COMMERCIAL DEVELOPMENT, US & EUROPE
  • Yuhong Qiu, Ph.D., SENIOR VICE PRESIDENT, GLOBAL REGULATORY AFFAIRS
  • Birk VanderweeΓ«n, SENIOR VICE PRESIDENT, GLOBAL MANUFACTURING & SUPPLY
  • Alan Kick, SENIOR VICE PRESIDENT, GLOBAL QUALITY
  • Doug Wallace, VICE PRESIDENT, GLOBAL OPERATIONS
  • Elaine Qian, VICE PRESIDENT, GLOBAL HEAD OF HUMAN RESOURCES
  • Tim Roberts, Global Compliance Officer
  • Simon Wu, Senior Vice President, General Manager, Greater China
  • Frank Zhang, EMBA, Ph.D., CHAIRMAN OF THE BOARD, LEGEND BIOTECH
  • Sally Wang, M.S., PRESIDENT, GENSCRIPT
  • Zhu Li, Ph.D., CHIEF STRATEGY OFFICER, GENSCRIPT
  • Corazon (Corsee) Dating Sanders, Ph.D., CO-CHAIR OF THE BOARD OF ADVISORS, FRED HUTCH CANCER CENTER
  • Darren Ji, M.D., Ph.D. and MBA, CHAIRMAN AND CEO, ELPISCIENCE BIOPHARMACEUTICALS
  • Philip Yau, CHIEF FINANCIAL OFFICER. C&J CLARK
  • Patrick Casey, Ph.D., SENIOR VICE DEAN OF RESEARCH, DUKE-NUS MEDICAL SCHOOL SINGAPORE AND A JAMES B. DUKE PROFESSOR OF PHARMACOLOGY AND CANCER BIOLOGY, DUKE UNIVERSITY
  • Tomas J. Heyman, CEO, INTERLAKEN THERAPEUTICS
  • Li Mao, M.D., CHIEF MEDICAL OFFICER, SCICLONE PHARMACEUTICALS
  • Peter Salovey, Ph.D., Chris Argyris Professor of Psychology; Professor of Management, Epidemiology & Public Health, and Sociology; and President Emeritus of Yale University
  • Michel Vounatsos, FORMER CEO OF BIOGEN INC.
  • John Maraganore, Ph.D., FORMER CEO OF ALNYLAM PHARMACEUTICALS

Last updated: 2024-12-31

Nkarta, Inc.

Nkarta, Inc. logo
Market Cap: Low
Employees: Low

NKX101 and NKX019

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies for the treatment of cancer. The company specializes in cellular immunotherapy using chimeric antigen receptors on natural killer cells to target tumor antigens.

Tags: NK cells, biopharmaceutical, cancer treatment, cell therapy, clinical trials, immunotherapy

Symbol: NKTX

Recent Price: $2.32

Industry: Biotechnology

CEO: Mr. Paul J. Hastings

Sector: Healthcare

Employees: 150

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 582 4923

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31

Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

XCART

Xenetic Biosciences, Inc. is a biopharmaceutical company that focuses on advancing XCART, a personalized CAR T platform technology for oncology therapeutics and biologic drug development.

Tags: CAR T, biopharmaceutical, biotechnology, drug delivery, oncology, therapeutics

Symbol: XBIO

Recent Price: $4.05

Industry: Biotechnology

CEO: Mr. James F. Parslow

Sector: Healthcare

Employees: 4

Address: 40 Speen Street, Framingham, MA 01701

Phone: 781 778 7720

Leadership

  • James F. Parslow, Interim Chief Executive Officer and Chief Financial Officer
  • Scott N. Cullison, Business Development
  • Reid P. Bissonnette, Ph.D., Translational Research and Development
  • Cory C. Kauffman, Ph.D., Chief Technology Officer
  • Adam Logal, Chairman
  • Grigory G. Borisenko, Ph.D., Non-Executive Director
  • James Eric Callaway, Ph.D., Non-Executive Director
  • Firdaus Jal Dastoor, FCS, Non-Executive Director
  • Dmitry Genkin, MD, Non-Executive Director
  • Roger Kornberg, Ph.D., Non-Executive Director
  • Moshe Mizrahy, Non-Executive Director
  • Dr. Alexey Vinogradov, Non-Executive Director

Last updated: 2024-12-31

Arcus Biosciences, Inc.

Arcus Biosciences, Inc. logo
Market Cap: High
Employees: Medium

Cancer Therapies

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing and commercializing cancer therapies, with a pipeline including products like Etrumadenant, Zimberelimab, and Domvanalimab among others.

Tags: biopharmaceutical, cancer therapies, clinical trials, oncology

Symbol: RCUS

Recent Price: $14.91

Industry: Biotechnology

CEO: Dr. Terry J. Rosen Ph.D.

Sector: Healthcare

Employees: 577

Address: 3928 Point Eden Way, Hayward, CA 94545

Phone: 510 694 6200

Last updated: 2024-12-31

Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

Imm Celz

Creative Medical Technology Holdings, Inc. is a biotechnology company focusing on using adult stem cell treatments for immunology, urology, orthopedics, and neurology, offering solutions like Caver Stem, Fem Celz, Stem Spine, Imm Celz, and Ova Stem.

Tags: biotechnology, immunology, neurology, orthopedics, stem cell treatments, urology

Symbol: CELZ

Recent Price: $2.34

Industry: Biotechnology

CEO: Mr. Timothy Warbington

Sector: Healthcare

Employees: 4

Address: 211 East Osborn Road, Phoenix, AZ 85012

Phone: 480 399 2822

Last updated: 2024-12-31

Galecto, Inc.

Galecto, Inc. logo
Market Cap: Lowest
Employees: Lowest

GB2064

Galecto, Inc. is a clinical-stage biotechnology company focused on developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Their lead product candidate, GB2064, is in Phase IIa for myelofibrosis. The company also advances other candidates targeting severe fibrotic lung diseases and cancer.

Tags: biotechnology, cancer, clinical trials, fibrosis, inflammation, pharmaceutical

Symbol: GLTO

Recent Price: $4.60

Industry: Biotechnology

CEO: Dr. Hans T. Schambye M.D., Ph.D.

Sector: Healthcare

Employees: 13

Address: 75 State Street, Boston, MA 02109

Phone: 457 070 5210

Last updated: 2024-12-31

Immix Biopharma, Inc.

Immix Biopharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

IMX-110, IMX-111, IMX-120

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation, with clinical trials across the United States and Australia.

Tags: Biopharmaceuticals, Clinical Trials, Inflammation, Oncology, Tissue-Specific Therapeutics

Symbol: IMMX

Recent Price: $2.36

Industry: Biotechnology

CEO: Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.

Sector: Healthcare

Employees: 14

Address: 11400 West Olympic Boulevard, Los Angeles, CA 90064

Phone: 310 651 8041

Last updated: 2024-12-31